Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations

Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations

COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and...

Full description

Bibliographic Details
Main Authors: Andrea Favalli, Ennio Giulio Favalli, Andrea Gobbini, Elena Zagato, Mauro Bombaci, Gabriella Maioli, Elisa Pesce, Lorena Donnici, Paola Gruarin, Martina Biggioggero, Serena Curti, Lara Manganaro, Edoardo Marchisio, Valeria Bevilacqua, Martina Martinovic, Tanya Fabbris, Maria Lucia Sarnicola, Mariacristina Crosti, Laura Marongiu, Francesca Granucci, Samuele Notarbartolo, Alessandra Bandera, Andrea Gori, Raffaele De Francesco, Sergio Abrignani, Roberto Caporali, Renata Grifantini
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
COVID-19
DMARD
immune responses
rheumatic musculoskeletal diseases
inflammatory arthritis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.873195/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.873195/full

Similar Items